{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=15-day+taper+prednisone", "query": { "intervention": "15-day taper prednisone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=15-day+taper+prednisone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T09:24:17.447Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT02921789", "title": "Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation", "Primary Focal Segmental Glomerulosclerosis (FSGS)" ], "interventions": [ { "name": "Bleselumab", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Tacrolimus Capsules", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2017-05-22", "completion_date": "2021-05-18", "has_results": true, "last_update_posted_date": "2024-12-04", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 20, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921789" }, { "nct_id": "NCT02550652", "title": "A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Mycophenolate Mofetil/Mycophenolic Acid", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 126, "start_date": "2015-11-13", "completion_date": "2023-08-02", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 7, "location_summary": "La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Brooklyn", "state": "New York" }, { "city": "Great Neck", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02550652" }, { "nct_id": "NCT06598332", "title": "5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Graft-Versus-Host Disease(GVHD)" ], "interventions": [ { "name": "5-Azacytidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2025-08", "completion_date": "2029-05-01", "has_results": false, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06598332" }, { "nct_id": "NCT03663933", "title": "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Primary T-cell Immunodeficiency Disorders", "Immune System Diseases", "Common Variable Immunodeficiency" ], "interventions": [ { "name": "e-ATG", "type": "DRUG" }, { "name": "Immunosuppression Only Conditioning", "type": "PROCEDURE" }, { "name": "Reduced Intensity Conditioning", "type": "PROCEDURE" }, { "name": "GVHD Prophylaxis", "type": "DRUG" }, { "name": "Allogeneic HSC", "type": "PROCEDURE" }, { "name": "Bisulfan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "PFTs", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspirate & Biopsy", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "2D ECHO", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 71, "start_date": "2018-09-04", "completion_date": "2030-04-03", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663933" }, { "nct_id": "NCT00486421", "title": "Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Nonneoplastic Condition" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 22, "start_date": "2007-01", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2014-10-17", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00486421" }, { "nct_id": "NCT03292861", "title": "The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2018-09-13", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03292861" }, { "nct_id": "NCT00668434", "title": "Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sciatica" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 269, "start_date": "2008-11", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 3, "location_summary": "Redwood City, California • Roseville, California • San Jose, California", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Jose", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00668434" }, { "nct_id": "NCT00296244", "title": "Steroid Free Immunosuppression in Liver Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Liver Cirrhosis", "Liver Transplant Disorder" ], "interventions": [ { "name": "Steroids", "type": "DRUG" }, { "name": "Basiliximab", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Enteric-coated Mycophenolic acid (EC-MPA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 40, "start_date": "2006-02", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2012-11-19", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00296244" }, { "nct_id": "NCT04658927", "title": "Dextenza With ILUX for Treatment of MGD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Meibomian Gland Dysfunction", "Evaporative Dry Eye" ], "interventions": [ { "name": "Dexamethasone, 0.4mg", "type": "DRUG" }, { "name": "Prednisone acetate", "type": "DRUG" }, { "name": "Control", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Warrenville Eyecare", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-01-04", "completion_date": "2021-05-30", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-09-27T09:24:17.447Z", "location_count": 1, "location_summary": "Warrenville, Illinois", "locations": [ { "city": "Warrenville", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04658927" } ] }